Interleukin-2 and other cytokines

  • Jens Atzpodien
  • Axel Schomburg
  • Hartmut Kirchner
  • Hubert Poliwoda


In combining recombinant human interleukin-2 (IL-2) with other cytokines, a plethora of immunologic effects are exploited. Most of these host defense mechanisms, effects on tumour growth and on tumour differentiation are not yet fully understood [72].


Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Advanced Renal Cell Carcinoma Recombinant Interferon Recombinant Human Interferon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Agah R, Malloy B, Sherrod A, Mazumder A. Successfultherapy of natural killer-resistant pulmonary metastases by the synergism of7-interferon with tumour necrosis factor and interleukin-2 in mice. Cancer Res 1988; 48: 2245–8.PubMedGoogle Scholar
  2. 2.
    Aguet M, Mogensen KE. Interferon receptors. In: Gresser I, (editor).Interferon 3. New York: AcademicPress, 1983: 1–22.Google Scholar
  3. 3.
    Aprile JA, RussoM, Pepe MS, Loughran TP. Activation signals leading to proliferation of normaland leukemic CD3+ large granular lymphocytes. Blood 1991; 78: 1282–5.PubMedGoogle Scholar
  4. 4.
    AtzpodienJ, Shimazaki C, Wisniewski D, et al. Interleukin-2 und Interferon- in deradoptiven Immuntherapie des Plasmozytoms: Ein experimentelles Modell. In: LutzD, Heinz R, Nowotny H, Stacher A, et al. (editors). Leukämien und Lymphome.München, Wien, Baltimore: Urban & Schwarzenberg 1988: 211–2.Google Scholar
  5. 5.
    Atzpodien J,Kirchner H. Cancer, cytokines, and cytotoxic cells: Interleukin-2 in theimmunotherapy of human neoplasms. Klin Wochenschr 1990; 68: 1–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Atzpodien J,Körfer A, Franks CR, et al. Home therapy with recombinant interleukin-2 andinterferon-a2b in advanced human malignancies. Lancet 1990; 335: 1509–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Atzpodien J,Poliwoda H, Kirchner H. Alpha-interferon and interleukin-2 in renal cellcarcinoma: Studies in nonhospitalized patients. Semin Oncol 1991; 18: 108–12.PubMedGoogle Scholar
  8. 8.
    AtzpodienJ, Körfer A, Schomburg A, et al. Outpatient treatment of metastatic renal cellcarcinoma patients: Interleukin-2 in combination with interferon-a. Ann Oncol,1992. In press.Google Scholar
  9. Atzpodien J, Kirchner H, Schomburg A, et al. Outpatientchemo-immunotherapy of advanced malignant melanoma: sequential administration of scinterleukin-2 and interferon-a after iv dacarbazine and carboplatin. J ClinOncol, 1992. In press.Google Scholar
  10. AtzpodienJ, Kirchner H, Körfer A, et al. Treatment of metastatic colorectal cancerpatients with 5-fluorouracil in combinationwith recombinant subcutaneous human interleukin-2 and interferon-.Oncol, 1992. In press.Google Scholar
  11. 11.
    BaarsJW, Wagstaff J, Boven E, et al. Phase I study on the sequential administrationof recombinant human Interferon- and recombinant human Interleukin-2 inpatients with metastatic solid tumours. J Nat Cancer Inst, 1991; 83: 1408–10.PubMedCrossRefGoogle Scholar
  12. 12.
    BalkwillFR. Peptid regulatory factors: Interferons. Lancet 1, 1989; 1060–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Bash JA, ArroyoPA, Wiegand G, et al. Direct effects of alpha interferon (IFN-) on murineadenocarcinom C-C36 as a basis for synergywith interleukin-2 (IL-2) in cytolytic lymphocyte (CTL) mediatedabrogation of hepatic metastases. Proc AACR 1990; 31: 251.Google Scholar
  14. 14.
    Belosevic M, Finbloom DS, Meltzer MS, Nacy CA. IL-2. A cofactor forinduction of activated macrophageresistance to infection. J Immunol 1990; 145: 831–6.PubMedGoogle Scholar
  15. 15.
    Bergmann L,Weidmann E, Bungert B, et al. Influence of various cytokines on the inductionof lymphokine-activated killer cells. Nat Immun Cell Growth Regul 1990; 9:265–73.PubMedGoogle Scholar
  16. 16.
    Bergmann L,Weidmann E, Mitrou PS, et al. Interleukin-2 in combination with Interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. Aphase I/II study. Onkologie 1990; 13: 137–40.CrossRefGoogle Scholar
  17. 17.
    Blay JY,Bertoglio J, Fradelizi D, Chouaib S. Functional interactions of IL2 and TNF inthe differentiation of LGL into LAK effectors. Int J Cancer 1989; 44: 598–604.PubMedCrossRefGoogle Scholar
  18. 18.
    Borden EC. Augmented tumour-associated antigen expression by interferon.J Nat Cancer Inst 1988;80: 8–14.CrossRefGoogle Scholar
  19. 19.
    Bosse D, Ades E. Suppression of human immunoglobulin synthesis byInterleukin-4 in tandem withInterleukin-2 through large granular lymphocytes. Pathobiology 1991; 59: 391–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Braakman E, Van Tunen A, Meager A, Lucas CJ. IL-2- and IFN7-enhancednatural cytotoxic activity:Analysis of the role of different lymphoid subsets and implications foractivation routes. Cell Immunol 1986; 99: 476–88.PubMedCrossRefGoogle Scholar
  21. 21.
    Bradley EC, LouieAC, Paradise CM, et al. Antitumour response in patients with metastatic renalcell carcinoma is dependent upon regimen intensity. Proc ASCO 1989; 8: 133.Google Scholar
  22. 22.
    Brooks B, Chapman K, Lawry J, et al. Suppression oflymphokine-activated killer (LAK) cell induction mediated by Interleukin-4 andtransforming growth factor-βl: Effect of addition of exogenous tumournecrosis factor-alpha and Interferon-gamma, and measurement of their endogenousproduction. Clin Exp Immunol 1990; 82: 583–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Brooks CG,Holscher M, Urdal D. Natural killer activity in cloned cytotoxic T lymphocytes:Regulation by Interleukin 2, Interferon, and specific antigen. J Immunol 1985;135: 1145–52.PubMedGoogle Scholar
  24. 24.
    Brunda MJ, Rosenbaum D, Stern L. Inhibition of experimentally-inducedmurine metastases byrecombinant alpha interferon: correlation between the modulatory effect ofinterferon treatment on natural killer cell activity and inhibition ofmetastases. Int J Cancer 1984; 24: 421–6.CrossRefGoogle Scholar
  25. 25.
    Brunda MJ,Tarnowski D, Davatelis V. Interaction of recombinant Interferons with recombinant Interleukin-2: Differential effects onnatural killer cell activity and Interleukin-2- activated killer cells.Int J Cancer 1986; 37: 787–93.PubMedCrossRefGoogle Scholar
  26. 26.
    Brunda MJ, Bellantoni D, Sulich V. In vivo anti-tumour activity ofcombinations of Interferon alpha and Interleukin-2 in a murine model.Correlation of efficacy with the induction of cytotoxic cells resemblingnatural killer cells. Int J Cancer 1987; 40: 365–71.Google Scholar
  27. 27.
    Budd GT, OsgoodB, Barna B, et al. Phase I clinical trial of Interleukin 2 and -Interferon:Toxicity and immunologic effects. Cancer Res 1989; 49: 6432–6.PubMedGoogle Scholar
  28. 28.
    Bukowski RM, Murthy S, Sergi J, et al. Phase I trial of continuousinfusion recombinant Interleukin-2and intermittent recombinant Interferon-alpha 2a: Clinical effects. J BiolResponse Mod 1990; 9: 538–45.Google Scholar
  29. 29.
    Cameron RB,Mclntosh JK, Rosenberg SA. Synergistic antitumour effects of combination immunotherapy with recombinant Interleukin-2 and arecombinant hybrid -Interferon in the treatment of establishedmurine hepatic metastases. Cancer Res 1988; 48: 5810–7.PubMedGoogle Scholar
  30. 30.
    ChenBP, Sondel PM. Cytotoxicity of autologous Epstein-Barr virus-transformed cells mediated by interleukin-2 dependent, long-term Tcell cultures is augmented by beta, but not alpha, recombinantinterferon. J Biol Response Mod 1986; 5: 351–61.PubMedGoogle Scholar
  31. 31.
    Cheson BD, MartinA. Clinical trials in hairy cell leukemia: current status and futuredirections. Ann Intern Med 1987; 106: 871–8.PubMedGoogle Scholar
  32. 32.
    ChikkalaNF, Lewis I, Ulchaker J, et al. Interactive effects of -Interferon A/Dand Interleukin 2 on murine lymphokine-activated killer activity: Analysis atthe effector and precursor level. Cancer Res 1990; 50: 1176–82.PubMedGoogle Scholar
  33. 33.
    Chou T, Chang AE,Shu S. Generation of therapeutic T lymphocytes from tumour-bearing mice by invitro sensitization. J Immunol 1988; 140: 2453–61.PubMedGoogle Scholar
  34. 34.
    ChouaibS, Bertoglio J, Blay JY, et al. Generation of lymphokine-activated killercells: Synergy between tumour necrosis factor and Interleukin 2. Immunology1988; 85: 6875–9.Google Scholar
  35. 35.
    Coffman RL, Ohara J, Bond MW, et al. B cell stimulatory factor-1enhances the IgE response oflipopolysaccharide-activated B cells. J Immunol 1986; 136: 4538–41.PubMedGoogle Scholar
  36. 36.
    Cox GW, Mathieson BJ, Giardina SL, Varesio L.Characterization of IL-2 receptor expression and function on murinemacrophages. J Immunol 1990; 145: 1719–25.PubMedGoogle Scholar
  37. 37.
    Cox GW, Chattopadhyay U, Oppenheim JJ, Varesio L. IL-4inhibits the costimulatory activity of IL-2 or picolinic acid but not oflipopolysaccharide on sIFN-7-treated macrophages. J Immunol 1991; 147: 3809–14.PubMedGoogle Scholar
  38. 38.
    Creagan ET, Ahmann DL, Green SJ. Phase II study ofrecombinant leukocyte alpha interferon in disseminated malignant melanoma.Cancer 1984; 54: 2844–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Danis VA, FranicGM, Rathjen DA, Brooks PM. Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-2,interferon-gamma (IFN-), tumour necrosis factor-alpha (TNF-) and IL-6 on the production ofimmunoreactive Il-2 and TNF- by human monocytes. Clin Exp Immunol1991; 85: 143–450.PubMedCrossRefGoogle Scholar
  40. 40.
    Daugherty JP, Weiner LM. Augmentation of IL-2-induced11-2 receptor expression by IFN-. Proc AACR 1987;28:341.Google Scholar
  41. 41.
    DeFranceT, Vanbervliet B, Aubry J, et al. B cell growth-promoting activity ofrecombinant human interleukin-4. J Immunol 1987; 139: 1135–41.PubMedGoogle Scholar
  42. 42.
    DeFrance T, Vanbervliet B, Aubry J, Banchereau J.Interleukin-4 inhibits the proliferation but not the differentiation ofactivated human B cells in response to interleukin-2. J Exp Med 1988; 168: 1321–33.PubMedCrossRefGoogle Scholar
  43. 43.
    DiRaimondo F, LaPushin R, Hersh EM. Synergism between alpha-Interferonand Interleukin- 2-activatedkiller cells: In vitro studies. Acta Haematol 1987; 78: 77–83.CrossRefGoogle Scholar
  44. 44.
    Dubinett SM, Kurnick JT, Kradin RL. Analysis of the local inflammatoryresponse to adoptive immunotherapywith activated lymphocytes, IFN-gamma, and IL-2. FASEB J 1988; 2: 2286.Google Scholar
  45. 45.
    Dutcher JP, Creekmore S, Weiss GR, Atkins MB. A phase IIstudy of interleukin-2 and LAK cells in patients with metastatic malignantmelanoma. J Clin Oncol 1989; 7: 477–85.PubMedGoogle Scholar
  46. 46.
    Edwards BS, Hawkins MJ, Borden EC. Comparative in vivoand in vitro activation of human natural killercells by two recombinant -Interferons differing in antiviral activity.Cancer Res 1984;44:3135–39.PubMedGoogle Scholar
  47. 47.
    Edwards BS, Merritt JA, Fuhlbrigge RC, Borden EC. Low doses ofinterferon alpha result in more effective clinical natural killer cellactivation. J Clin Invest 1985; 75: 1908–13.PubMedCrossRefGoogle Scholar
  48. 48.
    Espevik T, Figari I, Ranges GE, Palladino MA. Transforming growthfactor-β1 (TGF-β1) and recombinant human tumour necrosis factora reciprocally regulate the generation of lymphokine-activated killer cellactivity. J Immunol 1988; 140: 2312–6.PubMedGoogle Scholar
  49. 49.
    Farace F, Mathiot C, Brandely M, et al. Phase I trial with recombinantInterleukin-2 (rIL-2): Immuneactivation by rIL-2 alone or following pretreatment with recombinantInterferon- gamma. Clin Exp Immunol 1990; 82: 194–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Favrot M, Capdeville R, Combaret V, et al. Functionaland phenotypic modifications induced by IL-4, as single agent or in combinationwith IL-2, on PBMC preactivated in vivo by alpha- Interferon +Interleukin-2 therapy. European Cytokine Network 1990; 1: 141–7.PubMedGoogle Scholar
  51. 51.
    Favrot M, Combaret V, Blay JY, et al. TNF alpha enhancement of NK andLAK cell functions inducedby high-dose IL-2 in human peripheral blood mononuclear cells from patientspretreated with alpha IFN + IL-2. European Cytokine Network 1990; 1: 221–7.PubMedGoogle Scholar
  52. 52.
    Figlin RA,Belldegrun A, Moldawer N, et al. Concomitant administration of recombinanthuman Interleukin-2 and recombinant Interferon alfa-2A: An active outpatientregimen in metastatic renal cell carcinoma. J Clin Oncol 1992; 10: 414–21.PubMedGoogle Scholar
  53. 53.
    Fisher RI, Coltman CA, Doroshow JH, Paietta EL. Metastatic renal cancertreated with interleukin-2and LAK cells. Ann Intern Med 1988; 108: 518–23.PubMedGoogle Scholar
  54. 54.
    Gallagher G, Wilcox F, Al-Azzawi F. Interleukin-3 and Interleukin-4 eachstrongly inhibit the inductionand function of human LAK cells. Clin Exp Immunol 1988; 74: 166–70.PubMedGoogle Scholar
  55. 55.
    Gerosa F, TommasiM, Gerosa M, Tridente G. Human recombinant interleukin-4 inhibitslymphokine-activated killer activity of sheep erythrocyte rosette-forming (E +) and -non- forming (E-) human lymphocytes. Int J Cancer 1988; 42: 902–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Gracomini P, AguzziA, Pestka S. Modulation by recombinant DNA leukocyte (alpha) and fibroblast(beta) interferons of the expression and shedding of HLA and tumour-associatedantigens by human melanoma cells. J Immunol 1984; 133: 1649–55.Google Scholar
  57. Hamblin J, DaviesB, Sadullah S, et al. A phase II study of the treatment of metastatic malignantmelanoma with a combination of dacarbazine, cis-platin, interleukin-2 (IL-2)and alfa-interferon (IFN). Eur J Cancer 1991; 27:Google Scholar
  58. 58.
    Haranaka K,Satomi N, Sakurai A. Anti-tumour activity of tumour necrosis factor against transplantable murine tumours andheterotransplanted human tumours in nude mice. Int J Cancer 1984; 34:263–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Henney CS,Kuribayashi K, Kern DF, Gillis S. Interleukin-2 augments natural killer cellactivity. Nature 1981; 291: 335–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Herberman RB, Ortaldo JR, Mantovani A, et al. Effect of humanrecombinant interferon on cytotoxicactivity of natural killer cells and monocytes. Cell Immunol 1982; 67: 160–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Herrmann F, Gebauer G, Lindemann A, et al. Interleukin-2 andinterferon-gamma recruit differentsubsets of human peripheral blood monocytes to secrete interleukin-1 and tumournecrosis factor-alpha. Clin Exp Immunol 1989; 77: 97.PubMedGoogle Scholar
  62. 62.
    Hersh EM, MurrayJL, Hong WK, et al. Phase I study of cancer therapy with recombinantinterleukin-2 administered by intravenous bolus injection. Biotherapy 1989; 1:215–26.PubMedCrossRefGoogle Scholar
  63. 63.
    Higuchi CM,Thompson JA, Lindgren CG, et al. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytespreactivated by interleukin 2 in vivo or in vitro. Cancer Res 1989; 49:6487–92.PubMedGoogle Scholar
  64. 64.
    Hirsh M, LiptonA, Harvey H, et al. Phase I study of Interleukin-2 and Interferon alfa-2a asoutpatient therapy for patients with advanced malignancy. J Clin Oncol 1990; 8:1657–63.PubMedGoogle Scholar
  65. 65.
    Houghton AN, Thomson TM, Gross D, et al. Surface antigens of melanomaand melanocytes. Specificityof induction of la antigens by human interferon. J Exp Med 1984; 160: 255–69.PubMedCrossRefGoogle Scholar
  66. 66.
    Huberman M,Bering H, Fallon B, et al. A phase I study of an outpatient regimen ofrecombinant human Interleukin-2 and alpha-2a-Interferon in patients with solidtumours. Cancer 1991; 68: 1708–13.PubMedCrossRefGoogle Scholar
  67. 67.
    Iigo M, Sakurai M, Shimizu M, et al. Synergistic inhibition of thegrowth of adenocarcinoma 755 by the combination of interleukin-2 and interferon-ß.Proc Jpn Acad Ser B 1986; 62:275–8.CrossRefGoogle Scholar
  68. 68.
    Iigo M, SakuraiM, Tamura T, et al. In vivo antitumour activity of multiple injections of recombinant Interleukin 2, alone and incombination with three different types of recombinant Interferon, onvarious syngeneic murine tumours. Cancer Res 48: 1988; 260–4.PubMedGoogle Scholar
  69. Isaacs A, Lindenmann J: Virus interference. 1. Theinterferons. Proc R Soc Biol Sci 147: 258.Google Scholar
  70. 70.
    Itoh K, Shiiba K, Shimizu Y, et al. Generation of activated killer (AK)cells by recombinant Interleukin-2 (rIL 2) in collaboration with Interferon-(IFN-). J Immunol 1985; 134: 3124–9.PubMedGoogle Scholar
  71. 71.
    Jelinek DF,Lipsky PE. Inhibitory influence of IL-4 on human B cell responsiveness. JImmunol 1988; 141: 164–73.Google Scholar
  72. 72.
    Kanz L, Brugger W, Bross K, Mertelsmann R. Combination of cytokines:Current status and futureprospects. Br J Haematol 1991; 79: 96–104.PubMedCrossRefGoogle Scholar
  73. 73.
    Karray S, Defranee T, Merle-Beral H, Banchereau J, et al. Interleukin-4counteracts the interleukin-2induced proliferation of monoclonal B cells. J Exp Med 1988; 168: 85–97.PubMedCrossRefGoogle Scholar
  74. 74.
    Kasid A, Bell GI,Director EP. Effects of transforming growth factor-β on human lymphokine-activated killer cell precursors:Autocrine inhibition of cellular proliferation and differentiation toimmune killer cells. J Immunol 1988; 141: 690–8.PubMedGoogle Scholar
  75. 75.
    Kaufmann Y,Davidsohn J, Levanon M, et al. Lymphokine-activated killer (LAK) cells:Interferon-7 synergizes with Interleukin-2 to induce LAK cytotoxicity inhomogeneous leukemic preparations. Clin Immunol Immunophathol 1991; 58: 278–88.CrossRefGoogle Scholar
  76. 76.
    Kawakami Y,Rosenberg SA, Lotze MT. Interleukin 4 promotes the growth of tumour-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med1988; 168: 2183–91.PubMedCrossRefGoogle Scholar
  77. 77.
    Kawakami Y, Custer MC, Rosenberg SA, Lotze MT. IL-4 regulates IL-2induction of lymphokine-activated killer activity from humanlymphocytes. J Immunol 1989; 142: 3452–61.PubMedGoogle Scholar
  78. 78.
    Keilholz U,Scheibenbogen C, Tilgen W, et al. Treatment of metastatic melanoma withinterferon and interleukin-2: Significant improvement with a newdosing schedule. Onkologie 1991; 14: 82.Google Scholar
  79. 79.
    Kim B, FranceschiD, Helman S, et al. Interferon inhibition of IL-2-mediated lymphocyteproliferation. Surgery 1988; 104: 390–7.PubMedGoogle Scholar
  80. 80.
    Kim B, Stein S, Warnaka P. Franceschi D. Enhanced in vivo therapy ofpulmonary metastases withInterferon and Interleukin-2. J Surg Res 1988; 45: 66–73.PubMedCrossRefGoogle Scholar
  81. 81.
    Kim B, Warnaka P.Enhanced survival of IFN-] augmented IL-2 therapy of pulmonary metastases: Efficacy comparable to Interleukin-2and lymphokine activated killer cells. J Surg Res 1991;50:40–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Kirchner H, Körfer A, Evers P, et al. The development of neutralizingantibodies in a patient receivingsubcutaneous recombinant and natural interleukin-2. Cancer 1991; 67: 1862–4.PubMedCrossRefGoogle Scholar
  83. 83.
    Kleinermann ES, Kurzrock R, Wyatt D, et al. Activation or suppressionof the tumouricidal properties of monocytes from cancer patients followingtreatment with human recombinant -interferon. Cancer Res 1986; 46:5401–5.Google Scholar
  84. 84.
    Knop J, TaborskiB, DeMaeyer-Guignard J. Selective inhibition of the generation of T suppressorcells of contact sensitivity in vitro by interferon. J Immunol 1987; 138:3684–7.PubMedGoogle Scholar
  85. 85.
    Koeffler HP, Ranyard J, Yelton L. Gamma interferon induces expressionof HLA-D antigen onnormal and leukemic human myeloid cells. Proc Nat Acad Sci USA 1984; 81:4080–4.PubMedCrossRefGoogle Scholar
  86. 86.
    Kornbluth J,Hoover RG. Changes in gene expression associated with IFN-β and IL-2-induced augmentation of human natural killer cell function. J Immunol 1988;141: 3234–40.PubMedGoogle Scholar
  87. 87.
    Krigel RL,Padavic-Shaller KA, Rudolph AR, et al. A phase I study of recombinantInterleukin 2 plus recombinant β-Interferon. Cancer Res 1988; 48: 3875–81.PubMedGoogle Scholar
  88. 88.
    Krigel RL, Padavic-Shaller KA, Rudolph AR, et al. Renal cell carcinoma:Treatment with recombinantInterleukin-2 plus Beta-Interferon. J Clin Oncol 1990; 8: 460–7.PubMedGoogle Scholar
  89. 89.
    Krown SE.Interferon treatment of renal cell carcinoma: Current status and future prospectives.Cancer 1987; 59: 647–51.PubMedCrossRefGoogle Scholar
  90. 90.
    Kruit WHJ, GoeySH, Monson JRT, et al. Clinical experience with the combined use of recombinantinterleukin2 (IL2) and interferon alfa-2a (IFN) in metastatic melanoma.Br J Haematol 1991; 79: 84–6.PubMedCrossRefGoogle Scholar
  91. 91.
    Kuribayashi K,Gillis S, Kern DE, Henney CS. Murine NK cell cultures: Effects of Interleukin-2and Interferon on cell growth and cytotoxic reactivity. J Immunol 1981; 126:2321–7.PubMedGoogle Scholar
  92. 92.
    Lauzon W, Lemaire I. Effects of biological response modifiers on lungnatural killer activity. ImmunopharmacolImmunotoxicol 1991; 13: 237–50.CrossRefGoogle Scholar
  93. 93.
    Lee KH, Talpaz M, Rothberg JM, et al. Concomitant administration ofrecombinant human Interleukin-2and recombinant interferon -2A in cancer patients: A phase I study. JClin Oncol 1989; 7: 1726–32.Google Scholar
  94. 94.
    Lee SH, Chiu H, Rinderknecht E, et al. Importance oftreatment regimen of interferon as an antitumour agent. Cancer Res 1983; 43:4172–5.PubMedGoogle Scholar
  95. 95.
    Legha SS.Interferons in the treatment of malignant melanoma. A review of recent trials.Cancer 1986; 57: 1675–7.PubMedCrossRefGoogle Scholar
  96. Legha SS, Ring S, Plager C, et al. Biochemotherapy usinginterleukin-2 (IL-2) + interferon alfa 2-A (IFN) in combination withcisplatin (C), vinblastine (V) and DTIC (D) in advanced melanoma. Proc AACO1991; 10: 293.Google Scholar
  97. 97.
    Lopez Hänninen E,Körfer A, Hadam M, et al. Biological monitoring of low-dose interleukin 2 in humans: Soluble interleukin-2 receptors,cytokines, and cell surface phenotypes. Cancer Res 1991; 50: 6312–6.Google Scholar
  98. 98.
    Lynch DH, NamenAE, Miller RE. In vivo evaluation of the effects of Interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy ofanti-tumour cytotoxic T lymphocytes. Eur J Immunol 1991;21:2977–85.PubMedCrossRefGoogle Scholar
  99. 99.
    Mandelli F,Tribalto M, Avvisati G. Recombinant interferon-alpha-2b as post-inductiontherapy for responding multiple myeloma patients. Cancer Treat Rev 1988; 15:43–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Martinez OM,Gibbons RS, Garovoy MR, Aronson FR. IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation ofhuman T cells. J Immunol 1990; 144: 2211–5.PubMedGoogle Scholar
  101. 101.
    McBride WH, Economou JS, Nayersina R, et al. Influences of interleukins2 and 4 on tumour necrosisfactor production by murine mononuclear phagocytes. Cancer Res 1990; 50:2949–57.PubMedGoogle Scholar
  102. 102.
    Mclntosh JK, MuléJJ, Merino MJ, Rosenberg SA. Synergistic antitumour effects of immunotherapy with recombinant Interleukin-2 andrecombinant tumour necrosis factor-. Cancer Res 1988; 48: 4011–7.Google Scholar
  103. 103.
    Mclntosh JK, Mule JJ, Krosnick JA, Rosenberg SA. Combination cytokine immunotherapywith tumour necrosis factor , Interleukin 2, and -Interferon andits synergistic antitumour effects in mice. Cancer Res 1989; 49: 1408–14.Google Scholar
  104. 104.
    Mitchell LC, Davis LS, Lipsky PE. Promotion of human T lymphocyteproliferation by IL-4. JImmunol 1989; 142: 1548–53.Google Scholar
  105. 105.
    Mittelman A,Puccio C, Ahmed T, et al. A phase II trial of Interleukin-2 by continuousinfusion and Interferon by intramuscular injection in patients with renal cellcarcinoma. Cancer 1991; 68: 1699–1702.PubMedCrossRefGoogle Scholar
  106. 106.
    Mosmann TR, BondMW, Coffman RL, et al. T cell and mast cell lines respond to B cell stimulatoryfactor-1. Proc Natl Acad Sci USA 1980; 83: 5654.CrossRefGoogle Scholar
  107. 107.
    Moxey-Mims MM,Simms H, Frank MM, et al. The effects of IL-1, IL-2, and tumour necrosis factoron polymorphonuclear leukocyte FC receptor-mediated phagocytosis: IL-2down-regulates the effect of tumour necrosis factor. J Immunol 1991; 147:1823–30.PubMedGoogle Scholar
  108. 108.
    Mule JJ, Smith GA, Rosenberg SA: Interleukin 4 (B cell stimulatoryfactor 1) can mediate the induction of lymphokin-activated killer cell activitydirected against fresh tumour cells. J Exp Med 1987; 166: 792–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Mule JJ, SchwartzSL, Roberts AB, et al. Transforming growth factor-beta inhibits the in vitrogeneration of lymphokine-activated killer cells and cytotoxic T cells. CancerImmunol Immunother 1988; 26: 95–102.Google Scholar
  110. 110.
    Murray JL, PillowJK, Rosenblum MG. Differential in vitro effects of alpha recombinant interferonand gamma recombinant interferon on the expression of melanoma-associatedantigens. Proc AACR 1986; 27: 313.Google Scholar
  111. 111.
    Muss HB.Interferon therapy for renal cell carcinoma. Semin Oncol 1987; 15: 36–42.Google Scholar
  112. 112.
    Narumi S, Finke JH, Hamilton TA. Interferon gamma and interleukin 2synergize to induce selectivemonokine expression in murine peritoneal macrophages. J Biol Chem 1990; 265:7036–41.PubMedGoogle Scholar
  113. 113.
    Nathan CF, Murray HW, Wiebe ME. Identification of interferon-gamma asthe lymphokine thatactivates human macrophage oxidative metabolism and antimicrobial activity. JExp Med 1983; 158: 670–89.CrossRefGoogle Scholar
  114. 114.
    Nedwin GE,Svedersky LP, Bringman TS, et al. Effect of Interleukin 2, Interferon-,and mitogens on the production of tumournecrosis factors and ßJ Immunol 1985; 135:2492–7.PubMedGoogle Scholar
  115. 115.
    Netaji B, MurthyS, Budd GT, et al. Phase IA/IB trial of interleukin-2 and interleukin-4 inrefractory malignancy: Toxicity and immunologic changes. Proc AACR 1991; 32:193.Google Scholar
  116. 116.
    Nishimura T, Ohta S, Sato N, et al. Combination tumour-immunotherapywith recombinant tumour necrosis factor and recombinant Interleukin-2 inmice. Int J Cancer 1987; 40: 255–61.PubMedCrossRefGoogle Scholar
  117. 117.
    Noelle R, Krammer PH, Ohara J, et al. Increased expression of laantigens on resting B cells: an additional role for B-cell growth factor. ProcNat Acad Sci USA 1984; 81: 6149–53.CrossRefGoogle Scholar
  118. 118.
    Olencki T, NatajiB, Budd GT, et al. Phase I trial of rIL-2 and rhuIL-4 in patients withrefractory malignancy: Hematologic and immunologic effects. Blood 1991; 78:439a.Google Scholar
  119. 119.
    Ostensen ME,Thiele DL, Lipsky PE. tumour necrosis factor- enhances cytolytic activityof human natural killer cells. J Immunol 1987; 138: 4185–91.PubMedGoogle Scholar
  120. 120.
    Ottesen SS,Ahrenkiel V, Kieler J. Recombinant human interferon-7 exerts an anti- proliferative effects and modulates theexpression of human leukocyte antigens A, B, C, and DR. Cancer ImmunolImmunother 1990; 31: 93–8.CrossRefGoogle Scholar
  121. 121.
    Owen-Schaub LB,Gutterman JU, Grimm EA. Synergy of tumour necrosis factor and Interleukin 2 inthe activation of human cytotoxic lymphocytes: Effect of tumour necrosis factorand Interleukin 2 in the generation of human lymphokine-activatedkiller cell cytotoxicity. Cancer Res 1988; 48: 788–92.PubMedGoogle Scholar
  122. 122.
    Pace JL, Russell SW, Torres BA, et al. Recombinant mouse 7-interferoninduces the priming stepin macrophage activation for tumour cell killing. J Immunol 1983; 130: 2011–3.PubMedGoogle Scholar
  123. 123.
    Palladino MA,Czarniecki CW, Chiu HH, et al. Regulation of cytokine production and class II antigen expression by transforming growthfactor-β. J Cell Biochem 1987; (Suppl 11 A): 10.Google Scholar
  124. 124.
    Paolozzi F,Zamkoff K, Doyle M, et al. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractoryneoplastic diseases. J Biol Response Mod 1989; 8: 122–39.PubMedGoogle Scholar
  125. 125.
    Pichert G, JostLM, Fierz W, Stahel RA. Clinical and immune modulatory effects of alternativeweekly Interleukin-2 and Interferon alfa-2a in patients with advanced renalcell carcinoma and melanoma. Br J Cancer 1991; 63: 287–92.PubMedCrossRefGoogle Scholar
  126. 126.
    Puri RK, TravisWD, Rosenberg SA. In vivo administration of Interferon andInterleukin 2 induces proliferation oflymphoid cells in the organs of mice. Cancer Res 1990; 50: 5543–50.PubMedGoogle Scholar
  127. 127.
    Puri RK, LelandP. In vivo treatment with Interferon causes augmentation of IL-2 inducedlymphokine-activated killer cells in the organs of mice. Clin Exp Immunol 1991;85: 317–25.PubMedCrossRefGoogle Scholar
  128. 128.
    Quesada JR, RiosA, Swanson D. Antitumour activity of recombinant-derived interferon alpha inmetastatic renal cell carcinoma. J Clin Oncol 1985; 3: 1522–28.PubMedGoogle Scholar
  129. 129.
    Quesada JR,Alexanian R, Hawkins M, et al. Treatment of multiple myeloma with recombinantalpha-interferon. Blood 1986; 67: 275–8.PubMedGoogle Scholar
  130. 130.
    Quesada JR, HershEM, Manning J. Treatment of hairy-cell leukemia with recombinant alphainterferon. Blood 1986; 68: 493–7.PubMedGoogle Scholar
  131. 131.
    Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development bytransforming growth factor and reversal by recombinant tumour necrosis factor.J Exp Med 1987; 166: 991–8.PubMedCrossRefGoogle Scholar
  132. 132.
    Rawlinson L, Dalton BJ, Rogers K, Rees RC. The influence of interferon,alpha and gamma, singlyor in combination on human natural cell mediated cytotoxicity. Biosci Rep 1988;9: 459–56.Google Scholar
  133. 133.
    Redman BG,Flaherty L, Chou TH, et al. A phase I trial of recombinant Interleukin-2 combined with recombinant Interferon-gamma inpatients with cancer. J Clin Oncol 1990; 8: 1269–76.PubMedGoogle Scholar
  134. 134.
    Richards JM:Sequential chemo-immunotherapy for metastatic melanoma. Semin Oncol 1991; 18:91–95.PubMedGoogle Scholar
  135. 135.
    Rook AH, KehrlJH, Wakefield LM, et al. Effects of transforming growth factor ßon thefunctions of natural killer cells: Depressed cytolytic activity and blunting ofInterferon responsiveness. J Immunol 1986; 136: 3916–20.PubMedGoogle Scholar
  136. 136.
    Rosenberg SA, Lotze MT, Chang AE, et al. A progress report on thetreatment of 157 patients with advanced cancer using lymphokine-activated killercells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316: 889–97.PubMedCrossRefGoogle Scholar
  137. 137.
    Rosenberg SA, Schwarz SL, Spiess PJ. Combination immunotherapy forcancer: Synergistic antitumourinteractions of Interleukin-2, alfa Interferon, and tumour-infiltratinglymphocytes. J Natl Cancer Inst 1988; 80: 1393–7.PubMedCrossRefGoogle Scholar
  138. 138.
    Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use ofhigh-dose Interleukin-2 inthe treatment of 652 cancer patients. Ann Surg 1989; 210: 474–85.PubMedCrossRefGoogle Scholar
  139. 139.
    Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy withInterleukin-2 and alpha- Interferon for the treatment of patients with advancedcancer. J Clin Oncol 1989; 7: 1863–74.PubMedGoogle Scholar
  140. 140.
    Schipper H,Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the functional living index - cancer:development and validation. J Clin Oncol 1984; 2: 472–83.PubMedGoogle Scholar
  141. 141.
    Silagi S,Dutkowski R, Schaefer A. Eradication of mouse melanoma by combined treatmentwith recombinant human Interleukin 2 and recombinant murine Interferon- gamma.Int J Cancer 1988; 41: 315–22.PubMedCrossRefGoogle Scholar
  142. 142.
    Sone S, Utsugi T,Nii A, Ogura T. Differential effects of recombinant Interferons , ßand on induction of human lymphokine (IL-2)-activated killer activity. JNatl Cancer Inst 1988; 80:425–31.CrossRefGoogle Scholar
  143. 143.
    Sosman JA, KohlerPC, Hank JA, Sondel PM. Repetitive weekly cycles of interleukin-2. Clinical andimmunologic effects of dose, schedule, and addition of indomethacin. J NatlCancer Inst 1988; 80: 1451–61.CrossRefGoogle Scholar
  144. 144.
    Spits H, Yssel H, Takebe Y, et al. Recombinant Interleukin 4 promotesthe growth of human Tcells. J Immunol 1987; 139: 1142–7.PubMedGoogle Scholar
  145. 145.
    Spits H, Yssel H,Paliard X, et al. IL-4 inhibits IL-2-mediated induction of humanlymphokine-activated killer cells, but not the generation of antigen-specificcytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol 1988; 141:29–36.PubMedGoogle Scholar
  146. 146.
    Splawski JB,Jelinek DF, Lipsky PE. Immunomodulatory role of IL-4 on the secretion of Ig byhuman B cells. J Immunol 1986; 142: 1569–75.Google Scholar
  147. 147.
    Sporn MB, RobertAB, Wakefield LM, Assoian RK. Transforming growth factor-β: biologicalfunction and chemical structure. Science 1986; 233: 532–4.PubMedCrossRefGoogle Scholar
  148. 148.
    Suzuki R, SuzukiS, Ebina N, Kumagai K. Suppression of alloimmune cytotoxic T lymphocyte (CTL)generation by depletion of NK cells and restoration by Interferon and/orInterleukin 2. J Immunol 1985; 134: 2139–48.PubMedGoogle Scholar
  149. 149.
    Svedersky LP,Shepard HM, Spencer SA, et al. Augmentation of human natural cell- mediatedcytotoxicity by recombinant human interleukin-2. J Immunol 1984; 133: 714–8.PubMedGoogle Scholar
  150. 150.
    Svedersky LP,Nedwin GE, Goeddel DV, et al. Interferon-7 enhances induction of lymphotoxin in recombinant Interleukin2-stimulated peripheral blood mononuclear cells. J Immunol 1985; 134:1604–8.PubMedGoogle Scholar
  151. 151.
    Sznol M Janik JE,Sharfman WH, et al. A phase Ia/lb study of subcutaneously (SQ) administered interleukin-2 (IL-2) in combinationwith interferon-alfa 2a (IFN). Proc AACO 1991; 10:209.Google Scholar
  152. 152.
    Talpaz M,Kantarjian HM, McCreedie K. Hematologic remission and cytogenetic improvementinduced by recombinant human interferon alpha A in chronic myelogenousleukemia. N Engl J Med 1986; 314: 1065–9.PubMedCrossRefGoogle Scholar
  153. 153.
    Tamura T. SasakiY, Shinkai T, et al. Phase I study of combination therapy with Interleukin 2and ß-Interferon in patients with advanced malignancy. Cancer Res. 1989; 49:730–5.PubMedGoogle Scholar
  154. 154.
    Thompson JA, LeeDJ, Lindgren CG, et al. Influence of dose and duration of interleukin-2 ontoxicity and immunomodulation. J Clin Oncol 1988; 6: 669–78.PubMedGoogle Scholar
  155. 155.
    Tokuda Y, EbinaN, Golub SH. The inhibitory effect of human Interferon alpha on the generation of lymphokine- activated killeractivity. Cancer Immunol Immunother 1989; 30: 205–12.PubMedCrossRefGoogle Scholar
  156. 156.
    Toledano M, Mathiot C, Michon J, et al. Interferon-7 and interleukin-2in the generation of lymphokine-activated killer cell cytotoxicity. CancerImmunol Immunother 1989; 30: 57–62.CrossRefGoogle Scholar
  157. 157.
    Treismann J, Higuchi CM, Thompson JA, et al. Enhancement by Interleukin4 of Interleukin 2-or antibody-induced proliferation of lymphocytes from Interleukin 2-treatedcancer patients. Cancer Res 1990; 50: 1160–4.Google Scholar
  158. 158.
    Truitt GA, SternLL, Bontempo J. Recombinant human Interleukin-2 (IL-2), alone and in combination with Interferon alpha, is a potentantitumour agent against colon 38 and Lewis lung carcinomas in mice.Proc AACR 1987; 28: 369.Google Scholar
  159. 159.
    Vaage J.Peri-tumour interleukin-2 causes systemic therapeutic effect via interferon-7induction. Int J Cancer 1991; 49: 598–600.PubMedCrossRefGoogle Scholar
  160. 160.
    VanDeGriend RJ, Ronteltap CPM, Gravekamp C, et al. Interferon-βand recombinant interleukin-2 can both enhance, but by different pathways, thenonspecific cytolytic potential of T3-negative natural killer cell-derived clonesrather than that of T3-positive clones. J Immunol 1986; 136: 1700–7.Google Scholar
  161. 161.
    Wahl SM, Hunt DA,Wong HL, et al. Transforming growth factor-β is a potent immunosuppressive agent that inhibitsIL-1-dependent lymphocyte proliferation. J Immunol 1988; 40: 3026–32.Google Scholar
  162. 162.
    Wan YJ, OrrisonBM, Lieberman R. Induction of major histocompatibility class I antigens byinterferons in undifferentiated F9 cells. J Cell Physiol 1987; 130: 276–83.PubMedCrossRefGoogle Scholar
  163. 163.
    Weiner LM,Padavic-Shaller K, Kitson J, et al. Phase I evaluation of combination therapywith interleukin 2 and 7-interferon. Cancer Res 1991; 51: 3910–8.PubMedGoogle Scholar
  164. 164.
    Weiss GR, MargolinKA, Aronson FR, et al. A randomized phase II trial of continuous infusioninterleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killercells for advanced renal cell carcinoma. J Clin Oncol 1992; 10: 275–81.PubMedGoogle Scholar
  165. 165.
    West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinantinterleukin-2 in adoptiveimmunotherapy of advanced cancer. N Engl J Med 1987; 316: 898–905.PubMedCrossRefGoogle Scholar
  166. 166.
    West WH. Clinicalapplication of continuous infusion of recombinant Interleukin-2. Eur J Cancer Clin Oncol 1989; 25: 11–15.Google Scholar
  167. 167.
    Widmer MB, AcresBR, Sassenfeld HM, Grabstein KH. Regulation of cytolytic cell populations from human peripheral blood by B cellstimulatory factor 1 (Interleukin 4). J Exp Med 1987; 166: 1447–55.PubMedCrossRefGoogle Scholar
  168. 168.
    Winkelhake JI, Stampfl S, Zimmerman RJ. Synergistic effects ofcombination therapy with humanrecombinant interleukin 2 and tumour necrosis factor in murine tumour models.Cancer Res 1987; 47: 3948–53.PubMedGoogle Scholar
  169. 169.
    Yang SC, Owen-Schaub LB, Grimm EA, Roth JA. Induction oflymphokine-activated killer cytotoxicity with interleukin-2 and tumour necrosisfactor- against primary lung cancer targets. Cancer Immunol Immunother1989; 29: 193–108.PubMedCrossRefGoogle Scholar
  170. 170.
    Yang SC, GrimmEA, Parkinson DR, et al. Clinical and immunomodulatory effects of combinationimmunotherapy with low-dose interleukin 2 and tumour necrosis factor inpatients with advanced non-small cell lung cancer: A phase I trial. Cancer Res1991; 51: 3669–76.PubMedGoogle Scholar
  171. 171.
    Zamkoff K, NewmanN, Paolozzi F, et al. A phase I study of recombinant interleukin-2 and recombinant beta interferon in patients withadvanced malignancy. Proc AACR 1987; 6: 242.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1993

Authors and Affiliations

  • Jens Atzpodien
  • Axel Schomburg
  • Hartmut Kirchner
  • Hubert Poliwoda

There are no affiliations available

Personalised recommendations